Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer.

about

Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q42366556

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Mutational status of TP53 defi ...... nt non-small cell lung cancer.

@en

Mutational status of TP53 defi ...... nt non-small cell lung cancer.

@nl

type

Item

label

Mutational status of TP53 defi ...... nt non-small cell lung cancer.

@en

Mutational status of TP53 defi ...... nt non-small cell lung cancer.

@nl

prefLabel

Mutational status of TP53 defi ...... nt non-small cell lung cancer.

@en

Mutational status of TP53 defi ...... nt non-small cell lung cancer.

@nl

P1476

Mutational status of TP53 defi ...... nt non-small cell lung cancer.

@en

P2093

Bo Mi Ku

http://www.w3.org/2001/XMLSchema#string

Jiae Koh

http://www.w3.org/2001/XMLSchema#string

Jin Seok Ahn

http://www.w3.org/2001/XMLSchema#string

Jong-Mu Sun

http://www.w3.org/2001/XMLSchema#string

Keunchil Park

http://www.w3.org/2001/XMLSchema#string

Myung-Ju Ahn

http://www.w3.org/2001/XMLSchema#string

Se-Hoon Lee

http://www.w3.org/2001/XMLSchema#string

Yeon-Hee Bae

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular pathways: targeting the dependence of mutant RAS cancers on the DNA damage response

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.

Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR

The DNA damage response: ten years after

Integrated functional, gene expression and genomic analysis for the identification of cancer targets

Expression and prognostic value of the WEE1 kinase in gliomas.

High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients.

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.

Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase.

P304

67526-67537

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.18728

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28978051

http://www.w3.org/2001/XMLSchema#string

P932

5620191

http://www.w3.org/2001/XMLSchema#string